The tenth study involving ReadiSorb® Glutathione has been published, showing absorption and immune support. The clinical study was conducted at a university clinic and is titled, Liposomal Glutathione Supplementation Restores TH1 Cytokine Response to Mycobacterium tuberculosis Infection in HIV-Infected Individuals.
The Individuals involved with the study had low glutathione related to HIV and the study showed that low glutathione is associated with a decrease in defensive function of immune cells. Furthermore, direct support using oral Liposomal Glutathione restores TH1 cell function and supports immune cell function related to fighting infection.
In Addition, the clinical study showed the role of glutathione in immune support. Th1 lymphocytes are critical in the cellular immune response and they play an important role in host defense system against microbial agents and viruses. In this study, tuberculosis bacteria were introduced into the participant’s immune cells in the lab. As a result, the growth of TB was significantly reduced in their cells after ingesting oral Liposomal Glutathione. The red outline in the graph below represents TB growth in the immune cells.
The study can be read in full on liebertpub.com.